<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01107899</url>
  </required_header>
  <id_info>
    <org_study_id>11983</org_study_id>
    <secondary_id>H7T-MC-TACM</secondary_id>
    <nct_id>NCT01107899</nct_id>
  </id_info>
  <brief_title>Study to Learn When Platelets Return to Normal After One Loading Dose of Anti-platelet Drugs in Patients With Symptoms of Acute Coronary Syndromes</brief_title>
  <official_title>Recovery of Platelet Function After a Loading Dose of Prasugrel or Clopidogrel in Aspirin-Treated Subjects Presenting With Symptoms of Acute Coronary Syndromes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Daiichi Sankyo Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate how platelets recover to normal function in subjects who have symptoms of a
      heart attack or unstable angina and who get a loading dose of prasugrel or clopidogrel for
      planned coronary angiography.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated due to Enrollment futility
  </why_stopped>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Returning to Baseline Platelet Function</measure>
    <time_frame>Days 3, 5, 7, 9, and 11</time_frame>
    <description>Participants were classified as having platelet function return to baseline after loading dose (LD) on the first day that P2Y12 Reaction Units (PRU) was no more than 60 PRU below baseline and remained in this range. PRU was assessed by Accumetrics Verify Now™ P2Y12. PRU represents the rate and extent of adenosine diphosphate (ADP)-stimulated platelet aggregation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Day on Which 50%, 75% and 90% of Subjects Return to Baseline Platelet Function Following a Single LD of 30-mg or 60-mg Prasugrel or 600-mg Clopidogrel</measure>
    <time_frame>Up through 11 days</time_frame>
    <description>This outcome measure was not analyzed due to the limited sample size.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Day When the Proportion of Participants Who Return to Baseline Platelet Function in the 30-mg and 60-mg Prasugrel Groups is Similar to the 600-mg Clopidogrel Group at Day 5 and Day 7</measure>
    <time_frame>Up through 11 days</time_frame>
    <description>The day at which the proportion of participants who return to baseline platelet P2Y12 receptor function in the prasugrel 30 mg and 60 mg LD groups is similar (within 10% absolute difference) to the proportion of subjects who return to baseline platelet P2Y12 receptor function at day 5 and day 7 in the clopidogrel 600 mg LD group, obtained from Kaplan Meier curves for the primary washout population, was to be presented. This outcome measure was not analyzed due to the limited sample size.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days to the Return of Baseline Platelet Function Following One Loading Dose (LD)</measure>
    <time_frame>Up through 11 days</time_frame>
    <description>The return of baseline platelet function following one LD of prasugrel (30 mg or 60 mg) or 600 mg LD of clopidogrel assessed by Verify Now™ P2Y12 Reaction Units (VN-PRU). This outcome measure was not analyzed because it was not appropriate to estimate the days based on the non-inferiority approach due to the limited sample size.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Initial Inhibition of Platelet Aggregation on the Day to Return to Baseline Platelet Function: VN-PRU</measure>
    <time_frame>Up through 11 days</time_frame>
    <description>To show effect of initial inhibition of platelet aggregation as measured by Accumetrics Verify Now™ P2Y12 on the day to return to baseline platelet function, a regression model was fitted with day to return as outcome variable and initial inhibition as fixed effect. Results are reported as the predicted day to return to baseline platelet function by derived VN-PRU percent (%) inhibition at 24 hours post LD. The derived VN-PRU % inhibition is calculated as a percent decrease of PRU from baseline using the following formula: ([PRU at baseline - PRU at 24 hours post LD]/PRU at baseline) x 100%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Days to the Return of Baseline Platelet Function in All Treatment Arms (Adjusted for Level of Inhibition 24 Hrs Post-LD) by VN-PRU</measure>
    <time_frame>Up through 11 days</time_frame>
    <description>PRU was assessed by Accumetrics Verify Now™ P2Y12. PRU represents the rate and extent of adenosine diphosphate (ADP)-stimulated platelet aggregation. This outcome measure was not analyzed due to the limited sample size.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet Function 24 Hours Post Loading Dose</measure>
    <time_frame>24 hours post-loading dose</time_frame>
    <description>PRU was assessed by Accumetrics Verify Now™ P2Y12. PRU represents the rate and extent of ADP-stimulated platelet aggregation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Poor Pharmacodynamic Responders by Platelet Aggregation at 24 Hours Post-LD</measure>
    <time_frame>24 hours post-loading dose</time_frame>
    <description>Platelet aggregation was assessed by Accumetrics Verify Now™ P2Y12, and poor responders were those with PRU greater than or equal to 230.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extent of Initial Inhibition of Platelet Aggregation on the Return of Baseline Platelet Function: Light Transmission Aggregometry (LTA)</measure>
    <time_frame>Up through 11 days</time_frame>
    <description>Initial inhibition of platelet aggregation was measured by LTA at 5 and 20 μM ADP. Maximum platelet aggregation (MPA) is reported by day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extent of Initial Inhibition of Platelet Aggregation to the Return of Baseline Platelet Function: Multiplate® ADP Test and ADP Test High Sensitivity (HS)</measure>
    <time_frame>Up through 11 days</time_frame>
    <description>Return of baseline platelet function was assessed by Multiplate® ADP test and ADP test High Sensitivity (HS). Multiplate analyzer was used to assess platelet aggregation based on impedance aggregometry in whole blood. The agonist ADP was added to stirred whole blood after dilution (1:2 with 0.9% NaCl solution) in a final concentration of 6.4 µM (ADP Test) or in final concentration of 6.4 µM ADP plus 9.4 nM Prostaglandin E1 (PGE1) (ADPtest HS). Platelet aggregation was continuously recorded for 5 minutes and quantified as area under the aggregation curve (AUC=AU*min) of aggregation units (AU).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Days to the Return of Baseline Platelet Function in All Treatment Arms (Adjusted for Level of Inhibition 24 Hours Post-LD) by LTA (5 and 20 μM ADP)</measure>
    <time_frame>Up through 11 days</time_frame>
    <description>Maximum platelet aggregation (MPA) to 5 and 20 μM ADP were assessed by LTA. This outcome measure was not analyzed due to limited sample size.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Days to the Return of Baseline Platelet Function in All Treatment Arms (Adjusted for Level of Inhibition 24 Hrs Post-LD) by Multiplate® ADP Test and ADP Test High Sensitivity (HS)</measure>
    <time_frame>Up through 11 days</time_frame>
    <description>The Multiplate analyzer was used to assess platelet aggregation based on impedance aggregometry in whole blood. After adding 6.4 µM ADP (ADP test) or 6.4 µM ADP plus 9.4 nM Prostaglandin E1 (PGE1) (ADP test HS), area under the aggregation curve (AUC) was calculated. This outcome measure was not analyzed due to limited sample size.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet Function by LTA at 5 and 20 μM ADP</measure>
    <time_frame>24 hours post-loading dose</time_frame>
    <description>MPA to 5 and 20 μM ADP were assessed by LTA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet Function by Multiplate® ADP Test and ADP Test HS</measure>
    <time_frame>24 hours post-loading dose</time_frame>
    <description>The Multiplate analyzer was used to assess platelet aggregation based on impedance aggregometry in whole blood. After adding 6.4 µM ADP (ADP test) or 6.4 µM ADP plus 9.4 nM PGE1 (ADP test HS), area under the aggregation curve (AUC) were calculated.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Acute Coronary Syndromes</condition>
  <arm_group>
    <arm_group_label>clopidogrel 600 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>prasugrel 60 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>prasugrel 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clopidogrel</intervention_name>
    <description>taken orally, day one, single dose</description>
    <arm_group_label>clopidogrel 600 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prasugrel</intervention_name>
    <description>taken orally, day one, single dose</description>
    <arm_group_label>prasugrel 60 mg</arm_group_label>
    <arm_group_label>prasugrel 30 mg</arm_group_label>
    <other_name>Efient®</other_name>
    <other_name>Effient®</other_name>
    <other_name>LY640315</other_name>
    <other_name>CS747</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women ≥18 to &lt;80 years of age who present with any one of the following:

          -  symptoms of Acute Coronary Syndromes (ACS)

          -  clinical symptoms of angina, or a positive stress test or who return for routine
             follow up angiography post stent placement in whom co-administration of aspirin and a
             thienopyridine (that is, clopidogrel, ticlopidine, or prasugrel) is not
             contraindicated

        Exclusion Criteria:

          -  Those presenting with ST-elevation MI (STEMI)

          -  histories of refractory ventricular arrhythmias

          -  an implanted defibrillator device

          -  congestive heart failure (NYHA Class III or above) within 6 months prior to screening

          -  significant hypertension

          -  subjects with a history or clinical suspicion of cerebral vascular malformations,
             transient ischaemic attack, or stroke

          -  bleeding disorders

          -  women known to be pregnant, who have given birth within the past 90 days, or who are
             breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Munich</city>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2010</study_first_submitted>
  <study_first_submitted_qc>April 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2010</study_first_posted>
  <results_first_submitted>December 1, 2011</results_first_submitted>
  <results_first_submitted_qc>December 1, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 12, 2012</results_first_posted>
  <last_update_submitted>March 7, 2012</last_update_submitted>
  <last_update_submitted_qc>March 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 9, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Coronary Syndromes</keyword>
  <keyword>Angina</keyword>
  <keyword>Platelet Function</keyword>
  <keyword>Coronary Angiography</keyword>
  <keyword>Clinical Symptoms of Angina</keyword>
  <keyword>Positive Stress Test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Clopidogrel 600 mg</title>
          <description>Clopidogrel 600 mg taken orally, day one, single dose (Loading Dose [LD])</description>
        </group>
        <group group_id="P2">
          <title>Prasugrel 60 mg</title>
          <description>Prasugrel 60 mg taken orally, day one, single dose (Loading Dose [LD])</description>
        </group>
        <group group_id="P3">
          <title>Prasugrel 30 mg</title>
          <description>Prasugrel 30 mg taken orally, day one, single dose (Loading Dose [LD])</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least One Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Loading Dose (LD) Intent to Treat (ITT)</title>
              <participants_list>
                <participants group_id="P1" count="5">Received LD and had evaluable pharmacodynamic (PD) measurements 24-hours post-LD.</participants>
                <participants group_id="P2" count="10">Received LD and had evaluable pharmacodynamic (PD) measurements 24-hours post-LD.</participants>
                <participants group_id="P3" count="6">Received LD and had evaluable pharmacodynamic (PD) measurements 24-hours post-LD.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>ITT Washout Population</title>
              <participants_list>
                <participants group_id="P1" count="5">ITT Washout Population (WP): Received LD, had evaluable baseline PD data (pre-LD) and post-LD.</participants>
                <participants group_id="P2" count="10">ITT Washout Population (WP): Received LD, had evaluable baseline PD data (pre-LD) and post-LD.</participants>
                <participants group_id="P3" count="6">ITT Washout Population (WP): Received LD, had evaluable baseline PD data (pre-LD) and post-LD.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Primary Washout Population</title>
              <participants_list>
                <participants group_id="P1" count="5">Primary WP: Completed study with no missed visits, had evaluable PD data through Day 11.</participants>
                <participants group_id="P2" count="10">Primary WP: Completed study with no missed visits, had evaluable PD data through Day 11.</participants>
                <participants group_id="P3" count="4">Primary WP: Completed study with no missed visits, had evaluable PD data through Day 11.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Clopidogrel 600 mg</title>
          <description>Clopidogrel 600 mg taken orally, day one, single dose (Loading Dose [LD])</description>
        </group>
        <group group_id="B2">
          <title>Prasugrel 60 mg</title>
          <description>Prasugrel 60 mg taken orally, day one, single dose (Loading Dose [LD])</description>
        </group>
        <group group_id="B3">
          <title>Prasugrel 30 mg</title>
          <description>Prasugrel 30 mg taken orally, day one, single dose (Loading Dose [LD])</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="9"/>
            <count group_id="B4" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.9" spread="8.54"/>
                    <measurement group_id="B2" value="65.6" spread="6.56"/>
                    <measurement group_id="B3" value="61.5" spread="10.01"/>
                    <measurement group_id="B4" value="64.8" spread="8.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Returning to Baseline Platelet Function</title>
        <description>Participants were classified as having platelet function return to baseline after loading dose (LD) on the first day that P2Y12 Reaction Units (PRU) was no more than 60 PRU below baseline and remained in this range. PRU was assessed by Accumetrics Verify Now™ P2Y12. PRU represents the rate and extent of adenosine diphosphate (ADP)-stimulated platelet aggregation.</description>
        <time_frame>Days 3, 5, 7, 9, and 11</time_frame>
        <population>Primary Washout Population: Included participants who completed the study, had evaluable pharmacodynamic (PD) data through Day 11. Participants with a missed visit were not included in the Primary Washout Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Clopidogrel 600 mg</title>
            <description>Clopidogrel 600 mg taken orally, day one, single dose (Loading Dose [LD])</description>
          </group>
          <group group_id="O2">
            <title>Prasugrel 60 mg</title>
            <description>Prasugrel 60 mg taken orally, day one, single dose (Loading Dose [LD])</description>
          </group>
          <group group_id="O3">
            <title>Prasugrel 30 mg</title>
            <description>Prasugrel 30 mg taken orally, day one, single dose (Loading Dose [LD])</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Returning to Baseline Platelet Function</title>
          <description>Participants were classified as having platelet function return to baseline after loading dose (LD) on the first day that P2Y12 Reaction Units (PRU) was no more than 60 PRU below baseline and remained in this range. PRU was assessed by Accumetrics Verify Now™ P2Y12. PRU represents the rate and extent of adenosine diphosphate (ADP)-stimulated platelet aggregation.</description>
          <population>Primary Washout Population: Included participants who completed the study, had evaluable pharmacodynamic (PD) data through Day 11. Participants with a missed visit were not included in the Primary Washout Population.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0"/>
                    <measurement group_id="O2" value="10.0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="60.0"/>
                    <measurement group_id="O3" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                    <measurement group_id="O3" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                    <measurement group_id="O3" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Day on Which 50%, 75% and 90% of Subjects Return to Baseline Platelet Function Following a Single LD of 30-mg or 60-mg Prasugrel or 600-mg Clopidogrel</title>
        <description>This outcome measure was not analyzed due to the limited sample size.</description>
        <time_frame>Up through 11 days</time_frame>
        <population>Since this outcome measure was not analyzed due to the limited sample size, zero participants were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Clopidogrel 600 mg</title>
            <description>Clopidogrel 600 mg taken orally, day one, single dose (Loading Dose [LD])</description>
          </group>
          <group group_id="O2">
            <title>Prasugrel 60 mg</title>
            <description>Prasugrel 60 mg taken orally, day one, single dose (Loading Dose [LD])</description>
          </group>
          <group group_id="O3">
            <title>Prasugrel 30 mg</title>
            <description>Prasugrel 30 mg taken orally, day one, single dose (Loading Dose [LD])</description>
          </group>
        </group_list>
        <measure>
          <title>The Day on Which 50%, 75% and 90% of Subjects Return to Baseline Platelet Function Following a Single LD of 30-mg or 60-mg Prasugrel or 600-mg Clopidogrel</title>
          <description>This outcome measure was not analyzed due to the limited sample size.</description>
          <population>Since this outcome measure was not analyzed due to the limited sample size, zero participants were included in the analysis.</population>
          <units>days</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Day When the Proportion of Participants Who Return to Baseline Platelet Function in the 30-mg and 60-mg Prasugrel Groups is Similar to the 600-mg Clopidogrel Group at Day 5 and Day 7</title>
        <description>The day at which the proportion of participants who return to baseline platelet P2Y12 receptor function in the prasugrel 30 mg and 60 mg LD groups is similar (within 10% absolute difference) to the proportion of subjects who return to baseline platelet P2Y12 receptor function at day 5 and day 7 in the clopidogrel 600 mg LD group, obtained from Kaplan Meier curves for the primary washout population, was to be presented. This outcome measure was not analyzed due to the limited sample size.</description>
        <time_frame>Up through 11 days</time_frame>
        <population>Since this outcome measure was not analyzed due to the limited sample size, zero participants were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel 60 mg</title>
            <description>Prasugrel 60 mg taken orally, day one, single dose (Loading Dose [LD])</description>
          </group>
          <group group_id="O2">
            <title>Prasugrel 30 mg</title>
            <description>Prasugrel 30 mg taken orally, day one, single dose (Loading Dose [LD])</description>
          </group>
        </group_list>
        <measure>
          <title>The Day When the Proportion of Participants Who Return to Baseline Platelet Function in the 30-mg and 60-mg Prasugrel Groups is Similar to the 600-mg Clopidogrel Group at Day 5 and Day 7</title>
          <description>The day at which the proportion of participants who return to baseline platelet P2Y12 receptor function in the prasugrel 30 mg and 60 mg LD groups is similar (within 10% absolute difference) to the proportion of subjects who return to baseline platelet P2Y12 receptor function at day 5 and day 7 in the clopidogrel 600 mg LD group, obtained from Kaplan Meier curves for the primary washout population, was to be presented. This outcome measure was not analyzed due to the limited sample size.</description>
          <population>Since this outcome measure was not analyzed due to the limited sample size, zero participants were included in the analysis.</population>
          <units>day</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days to the Return of Baseline Platelet Function Following One Loading Dose (LD)</title>
        <description>The return of baseline platelet function following one LD of prasugrel (30 mg or 60 mg) or 600 mg LD of clopidogrel assessed by Verify Now™ P2Y12 Reaction Units (VN-PRU). This outcome measure was not analyzed because it was not appropriate to estimate the days based on the non-inferiority approach due to the limited sample size.</description>
        <time_frame>Up through 11 days</time_frame>
        <population>Since this outcome measure was not analyzed due to the limited sample size, zero participants were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Clopidogrel 600 mg</title>
            <description>Clopidogrel 600 mg taken orally, day one, single dose (Loading Dose [LD])</description>
          </group>
          <group group_id="O2">
            <title>Prasugrel 60 mg</title>
            <description>Prasugrel 60 mg taken orally, day one, single dose (Loading Dose [LD])</description>
          </group>
          <group group_id="O3">
            <title>Prasugrel 30 mg</title>
            <description>Prasugrel 30 mg taken orally, day one, single dose (Loading Dose [LD])</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days to the Return of Baseline Platelet Function Following One Loading Dose (LD)</title>
          <description>The return of baseline platelet function following one LD of prasugrel (30 mg or 60 mg) or 600 mg LD of clopidogrel assessed by Verify Now™ P2Y12 Reaction Units (VN-PRU). This outcome measure was not analyzed because it was not appropriate to estimate the days based on the non-inferiority approach due to the limited sample size.</description>
          <population>Since this outcome measure was not analyzed due to the limited sample size, zero participants were included in the analysis.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Initial Inhibition of Platelet Aggregation on the Day to Return to Baseline Platelet Function: VN-PRU</title>
        <description>To show effect of initial inhibition of platelet aggregation as measured by Accumetrics Verify Now™ P2Y12 on the day to return to baseline platelet function, a regression model was fitted with day to return as outcome variable and initial inhibition as fixed effect. Results are reported as the predicted day to return to baseline platelet function by derived VN-PRU percent (%) inhibition at 24 hours post LD. The derived VN-PRU % inhibition is calculated as a percent decrease of PRU from baseline using the following formula: ([PRU at baseline - PRU at 24 hours post LD]/PRU at baseline) x 100%.</description>
        <time_frame>Up through 11 days</time_frame>
        <population>ITT Washout Population: All randomized participants who received study drug LD, had an evaluable baseline PD measurement (pre-LD), and had at least 1 evaluable PD measurement post-LD. One participant discontinued on Day 3 without returning to baseline and is not included in analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>All Treatments</title>
            <description>Clopidogrel 600 mg taken orally, day one, single dose Prasugrel 30 and 60 mg taken orally, day one, single dose
All treatments were combined into one group.</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Initial Inhibition of Platelet Aggregation on the Day to Return to Baseline Platelet Function: VN-PRU</title>
          <description>To show effect of initial inhibition of platelet aggregation as measured by Accumetrics Verify Now™ P2Y12 on the day to return to baseline platelet function, a regression model was fitted with day to return as outcome variable and initial inhibition as fixed effect. Results are reported as the predicted day to return to baseline platelet function by derived VN-PRU percent (%) inhibition at 24 hours post LD. The derived VN-PRU % inhibition is calculated as a percent decrease of PRU from baseline using the following formula: ([PRU at baseline - PRU at 24 hours post LD]/PRU at baseline) x 100%.</description>
          <population>ITT Washout Population: All randomized participants who received study drug LD, had an evaluable baseline PD measurement (pre-LD), and had at least 1 evaluable PD measurement post-LD. One participant discontinued on Day 3 without returning to baseline and is not included in analysis.</population>
          <units>days</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>20% Initial Inhibition</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40% Initial Inhibition</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60% Initial Inhibition</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>80% Initial Inhibition</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for the overall effect of initial inhibition on the day to return to baseline platelet function.</p_value_desc>
            <method>Regression, Linear</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Days to the Return of Baseline Platelet Function in All Treatment Arms (Adjusted for Level of Inhibition 24 Hrs Post-LD) by VN-PRU</title>
        <description>PRU was assessed by Accumetrics Verify Now™ P2Y12. PRU represents the rate and extent of adenosine diphosphate (ADP)-stimulated platelet aggregation. This outcome measure was not analyzed due to the limited sample size.</description>
        <time_frame>Up through 11 days</time_frame>
        <population>Since this outcome measure was not analyzed due to the limited sample size, zero participants were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Clopidogrel 600 mg</title>
            <description>Clopidogrel 600 mg taken orally, day one, single dose (Loading Dose [LD])</description>
          </group>
          <group group_id="O2">
            <title>Prasugrel 60 mg</title>
            <description>Prasugrel 60 mg taken orally, day one, single dose (Loading Dose [LD])</description>
          </group>
          <group group_id="O3">
            <title>Prasugrel 30 mg</title>
            <description>Prasugrel 30 mg taken orally, day one, single dose (Loading Dose [LD])</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Days to the Return of Baseline Platelet Function in All Treatment Arms (Adjusted for Level of Inhibition 24 Hrs Post-LD) by VN-PRU</title>
          <description>PRU was assessed by Accumetrics Verify Now™ P2Y12. PRU represents the rate and extent of adenosine diphosphate (ADP)-stimulated platelet aggregation. This outcome measure was not analyzed due to the limited sample size.</description>
          <population>Since this outcome measure was not analyzed due to the limited sample size, zero participants were included in the analysis.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Platelet Function 24 Hours Post Loading Dose</title>
        <description>PRU was assessed by Accumetrics Verify Now™ P2Y12. PRU represents the rate and extent of ADP-stimulated platelet aggregation.</description>
        <time_frame>24 hours post-loading dose</time_frame>
        <population>LD ITT population: All randomized participants who received an LD with evaluable PD measurements 24 hours post-LD.</population>
        <group_list>
          <group group_id="O1">
            <title>Clopidogrel 600 mg</title>
            <description>Clopidogrel 600 mg taken orally, day one, single dose (Loading Dose [LD])</description>
          </group>
          <group group_id="O2">
            <title>Prasugrel 60 mg</title>
            <description>Prasugrel 60 mg taken orally, day one, single dose (Loading Dose [LD])</description>
          </group>
          <group group_id="O3">
            <title>Prasugrel 30 mg</title>
            <description>Prasugrel 30 mg taken orally, day one, single dose (Loading Dose [LD])</description>
          </group>
        </group_list>
        <measure>
          <title>Platelet Function 24 Hours Post Loading Dose</title>
          <description>PRU was assessed by Accumetrics Verify Now™ P2Y12. PRU represents the rate and extent of ADP-stimulated platelet aggregation.</description>
          <population>LD ITT population: All randomized participants who received an LD with evaluable PD measurements 24 hours post-LD.</population>
          <units>P2Y12 Reaction Units (PRU)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="193.0" spread="83.58"/>
                    <measurement group_id="O2" value="32.5" spread="20.79"/>
                    <measurement group_id="O3" value="70.0" spread="56.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>p-value was obtained from an analysis of covariance model with treatment as a fixed effect and the baseline value as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>p-value was obtained from an analysis of covariance model with treatment as a fixed effect and the baseline value as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.025</p_value>
            <method>ANCOVA</method>
            <method_desc>p-value was obtained from an analysis of covariance model with treatment as a fixed effect and the baseline value as a covariate.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Poor Pharmacodynamic Responders by Platelet Aggregation at 24 Hours Post-LD</title>
        <description>Platelet aggregation was assessed by Accumetrics Verify Now™ P2Y12, and poor responders were those with PRU greater than or equal to 230.</description>
        <time_frame>24 hours post-loading dose</time_frame>
        <population>LD ITT Population: All randomized participants who received an LD with evaluable PD measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>Clopidogrel 600 mg</title>
            <description>Clopidogrel 600 mg taken orally, day one, single dose (Loading Dose [LD])</description>
          </group>
          <group group_id="O2">
            <title>Prasugrel 60 mg</title>
            <description>Prasugrel 60 mg taken orally, day one, single dose (Loading Dose [LD])</description>
          </group>
          <group group_id="O3">
            <title>Prasugrel 30 mg</title>
            <description>Prasugrel 30 mg taken orally, day one, single dose (Loading Dose [LD])</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Poor Pharmacodynamic Responders by Platelet Aggregation at 24 Hours Post-LD</title>
          <description>Platelet aggregation was assessed by Accumetrics Verify Now™ P2Y12, and poor responders were those with PRU greater than or equal to 230.</description>
          <population>LD ITT Population: All randomized participants who received an LD with evaluable PD measurements.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Extent of Initial Inhibition of Platelet Aggregation on the Return of Baseline Platelet Function: Light Transmission Aggregometry (LTA)</title>
        <description>Initial inhibition of platelet aggregation was measured by LTA at 5 and 20 μM ADP. Maximum platelet aggregation (MPA) is reported by day.</description>
        <time_frame>Up through 11 days</time_frame>
        <population>ITT Washout Population: All randomized participants who received the study drug LD, had an evaluable baseline PD measurement (pre-LD), and had at least 1 evaluable PD measurement post-LD.</population>
        <group_list>
          <group group_id="O1">
            <title>Clopidogrel 600 mg</title>
            <description>Clopidogrel 600 mg taken orally, day one, single dose (Loading Dose [LD])</description>
          </group>
          <group group_id="O2">
            <title>Prasugrel 60 mg</title>
            <description>Prasugrel 60 mg taken orally, day one, single dose (Loading Dose [LD])</description>
          </group>
          <group group_id="O3">
            <title>Prasugrel 30 mg</title>
            <description>Prasugrel 30 mg taken orally, day one, single dose (Loading Dose [LD])</description>
          </group>
        </group_list>
        <measure>
          <title>Extent of Initial Inhibition of Platelet Aggregation on the Return of Baseline Platelet Function: Light Transmission Aggregometry (LTA)</title>
          <description>Initial inhibition of platelet aggregation was measured by LTA at 5 and 20 μM ADP. Maximum platelet aggregation (MPA) is reported by day.</description>
          <population>ITT Washout Population: All randomized participants who received the study drug LD, had an evaluable baseline PD measurement (pre-LD), and had at least 1 evaluable PD measurement post-LD.</population>
          <units>percent platelet aggregation</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (20 μM ADP) (n=5, n=10, n=6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.00" lower_limit="61.82" upper_limit="74.18"/>
                    <measurement group_id="O2" value="72.70" lower_limit="65.31" upper_limit="80.09"/>
                    <measurement group_id="O3" value="76.33" lower_limit="66.76" upper_limit="85.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 (20 μM ADP) (n=5, n=10, n=6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.60" lower_limit="32.96" upper_limit="72.24"/>
                    <measurement group_id="O2" value="27.30" lower_limit="21.00" upper_limit="33.60"/>
                    <measurement group_id="O3" value="31.67" lower_limit="22.51" upper_limit="40.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 (20 μM ADP) (n=5, n=10, n=6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.00" lower_limit="40.25" upper_limit="71.75"/>
                    <measurement group_id="O2" value="42.50" lower_limit="37.69" upper_limit="47.31"/>
                    <measurement group_id="O3" value="46.33" lower_limit="33.38" upper_limit="59.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5 (20 μM ADP) (n=5, n=10, n=4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.40" lower_limit="59.41" upper_limit="81.39"/>
                    <measurement group_id="O2" value="47.00" lower_limit="42.50" upper_limit="51.50"/>
                    <measurement group_id="O3" value="58.25" lower_limit="41.24" upper_limit="75.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 (20 μM ADP) (n=5, n=10, n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.00" lower_limit="53.46" upper_limit="88.54"/>
                    <measurement group_id="O2" value="58.30" lower_limit="53.14" upper_limit="63.46"/>
                    <measurement group_id="O3" value="73.20" lower_limit="55.55" upper_limit="90.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9 (20 μM ADP) (n=5, n=10, n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.40" lower_limit="41.97" upper_limit="82.83"/>
                    <measurement group_id="O2" value="62.00" lower_limit="52.20" upper_limit="71.80"/>
                    <measurement group_id="O3" value="68.60" lower_limit="59.44" upper_limit="77.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11 (20 μM ADP) (n=5, n=10, n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.00" lower_limit="59.59" upper_limit="84.41"/>
                    <measurement group_id="O2" value="65.20" lower_limit="58.11" upper_limit="72.29"/>
                    <measurement group_id="O3" value="63.80" lower_limit="33.21" upper_limit="94.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline (5 μM ADP) (n=5, n=10, n=6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.40" lower_limit="60.21" upper_limit="68.59"/>
                    <measurement group_id="O2" value="62.60" lower_limit="55.76" upper_limit="69.44"/>
                    <measurement group_id="O3" value="70.67" lower_limit="65.42" upper_limit="75.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 (5 μM ADP) (n=5, n=10, n=6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.40" lower_limit="23.40" upper_limit="55.40"/>
                    <measurement group_id="O2" value="22.00" lower_limit="15.37" upper_limit="28.63"/>
                    <measurement group_id="O3" value="25.50" lower_limit="18.18" upper_limit="32.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 (5 μM ADP) (n=5, n=10, n=6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.20" lower_limit="36.31" upper_limit="64.09"/>
                    <measurement group_id="O2" value="32.80" lower_limit="28.73" upper_limit="36.87"/>
                    <measurement group_id="O3" value="48.67" lower_limit="38.85" upper_limit="58.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5 (5 μM ADP) (n=5, n=10, n=4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.20" lower_limit="48.17" upper_limit="80.23"/>
                    <measurement group_id="O2" value="39.50" lower_limit="34.26" upper_limit="44.74"/>
                    <measurement group_id="O3" value="53.25" lower_limit="38.23" upper_limit="68.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 (5 μM ADP) (n=5, n=10, n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.40" lower_limit="40.90" upper_limit="79.90"/>
                    <measurement group_id="O2" value="52.40" lower_limit="44.95" upper_limit="59.85"/>
                    <measurement group_id="O3" value="65.40" lower_limit="46.91" upper_limit="83.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9 (5 μM ADP) (n=5, n=10, n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.40" lower_limit="35.53" upper_limit="81.27"/>
                    <measurement group_id="O2" value="56.00" lower_limit="46.46" upper_limit="65.54"/>
                    <measurement group_id="O3" value="60.00" lower_limit="51.55" upper_limit="68.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11 (5 μM ADP) (n=5, n=10, n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.80" lower_limit="50.53" upper_limit="73.07"/>
                    <measurement group_id="O2" value="58.90" lower_limit="51.85" upper_limit="65.95"/>
                    <measurement group_id="O3" value="56.00" lower_limit="29.54" upper_limit="82.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Extent of Initial Inhibition of Platelet Aggregation to the Return of Baseline Platelet Function: Multiplate® ADP Test and ADP Test High Sensitivity (HS)</title>
        <description>Return of baseline platelet function was assessed by Multiplate® ADP test and ADP test High Sensitivity (HS). Multiplate analyzer was used to assess platelet aggregation based on impedance aggregometry in whole blood. The agonist ADP was added to stirred whole blood after dilution (1:2 with 0.9% NaCl solution) in a final concentration of 6.4 µM (ADP Test) or in final concentration of 6.4 µM ADP plus 9.4 nM Prostaglandin E1 (PGE1) (ADPtest HS). Platelet aggregation was continuously recorded for 5 minutes and quantified as area under the aggregation curve (AUC=AU*min) of aggregation units (AU).</description>
        <time_frame>Up through 11 days</time_frame>
        <population>ITT Washout Population: All randomized participants who received the study drug LD, had an evaluable baseline PD measurement (pre-LD), and had at least 1 evaluable PD measurement post-LD.</population>
        <group_list>
          <group group_id="O1">
            <title>Clopidogrel 600 mg</title>
            <description>Clopidogrel 600 mg taken orally, day one, single dose (Loading Dose [LD])</description>
          </group>
          <group group_id="O2">
            <title>Prasugrel 60 mg</title>
            <description>Prasugrel 60 mg taken orally, day one, single dose (Loading Dose [LD])</description>
          </group>
          <group group_id="O3">
            <title>Prasugrel 30 mg</title>
            <description>Prasugrel 30 mg taken orally, day one, single dose (Loading Dose [LD])</description>
          </group>
        </group_list>
        <measure>
          <title>Extent of Initial Inhibition of Platelet Aggregation to the Return of Baseline Platelet Function: Multiplate® ADP Test and ADP Test High Sensitivity (HS)</title>
          <description>Return of baseline platelet function was assessed by Multiplate® ADP test and ADP test High Sensitivity (HS). Multiplate analyzer was used to assess platelet aggregation based on impedance aggregometry in whole blood. The agonist ADP was added to stirred whole blood after dilution (1:2 with 0.9% NaCl solution) in a final concentration of 6.4 µM (ADP Test) or in final concentration of 6.4 µM ADP plus 9.4 nM Prostaglandin E1 (PGE1) (ADPtest HS). Platelet aggregation was continuously recorded for 5 minutes and quantified as area under the aggregation curve (AUC=AU*min) of aggregation units (AU).</description>
          <population>ITT Washout Population: All randomized participants who received the study drug LD, had an evaluable baseline PD measurement (pre-LD), and had at least 1 evaluable PD measurement post-LD.</population>
          <units>Aggregation Units * minutes</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (ADP) (n=5, n=10, n=6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="536.60" lower_limit="453.01" upper_limit="620.19"/>
                    <measurement group_id="O2" value="601.60" lower_limit="489.12" upper_limit="714.08"/>
                    <measurement group_id="O3" value="459.33" lower_limit="369.59" upper_limit="549.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 (ADP) (n=5, n=10, n=6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="248.80" lower_limit="133.88" upper_limit="363.72"/>
                    <measurement group_id="O2" value="90.00" lower_limit="74.08" upper_limit="105.92"/>
                    <measurement group_id="O3" value="118.17" lower_limit="79.82" upper_limit="156.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 (ADP) (n=5, n=10, n=6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="347.60" lower_limit="97.50" upper_limit="597.70"/>
                    <measurement group_id="O2" value="140.90" lower_limit="96.21" upper_limit="185.59"/>
                    <measurement group_id="O3" value="134.67" lower_limit="100.88" upper_limit="168.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5 (ADP) (n=5, n=10, n=4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="428.40" lower_limit="265.81" upper_limit="590.99"/>
                    <measurement group_id="O2" value="231.30" lower_limit="173.02" upper_limit="289.58"/>
                    <measurement group_id="O3" value="296.00" lower_limit="164.77" upper_limit="427.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 (ADP) (n=5, n=10, n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="478.80" lower_limit="338.41" upper_limit="619.19"/>
                    <measurement group_id="O2" value="316.20" lower_limit="257.51" upper_limit="374.89"/>
                    <measurement group_id="O3" value="295.40" lower_limit="229.77" upper_limit="361.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9 (ADP) (n=5, n=10, n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="529.40" lower_limit="381.37" upper_limit="677.43"/>
                    <measurement group_id="O2" value="549.00" lower_limit="439.70" upper_limit="658.30"/>
                    <measurement group_id="O3" value="484.40" lower_limit="316.20" upper_limit="652.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11 (ADP) (n=5, n=10, n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="555.00" lower_limit="431.41" upper_limit="678.59"/>
                    <measurement group_id="O2" value="500.20" lower_limit="426.84" upper_limit="573.56"/>
                    <measurement group_id="O3" value="564.00" lower_limit="439.67" upper_limit="688.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline (ADP HS) (n=5, n=10, n=6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="361.00" lower_limit="225.47" upper_limit="496.53"/>
                    <measurement group_id="O2" value="411.70" lower_limit="330.83" upper_limit="492.57"/>
                    <measurement group_id="O3" value="344.00" lower_limit="246.05" upper_limit="441.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 (ADP HS) (n=5, n=10, n=6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166.80" lower_limit="88.39" upper_limit="245.21"/>
                    <measurement group_id="O2" value="34.50" lower_limit="18.08" upper_limit="50.92"/>
                    <measurement group_id="O3" value="70.17" lower_limit="40.54" upper_limit="99.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 (ADP HS) (n=5, n=10, n=6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="257.60" lower_limit="41.96" upper_limit="473.24"/>
                    <measurement group_id="O2" value="79.30" lower_limit="55.45" upper_limit="103.15"/>
                    <measurement group_id="O3" value="90.50" lower_limit="64.84" upper_limit="116.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5 (ADP HS) (n=5, n=10, n=4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="256.80" lower_limit="118.58" upper_limit="395.02"/>
                    <measurement group_id="O2" value="114.10" lower_limit="87.86" upper_limit="140.34"/>
                    <measurement group_id="O3" value="145.00" lower_limit="72.29" upper_limit="217.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 (ADP HS) (n=5, n=10, n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="263.60" lower_limit="124.99" upper_limit="402.21"/>
                    <measurement group_id="O2" value="189.50" lower_limit="152.93" upper_limit="226.07"/>
                    <measurement group_id="O3" value="170.60" lower_limit="115.78" upper_limit="225.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9 (ADP HS) (n=5, n=10, n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="388.20" lower_limit="172.68" upper_limit="603.72"/>
                    <measurement group_id="O2" value="344.60" lower_limit="263.97" upper_limit="425.23"/>
                    <measurement group_id="O3" value="343.60" lower_limit="228.01" upper_limit="459.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11 (ADP HS) (n=5, n=10, n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="373.20" lower_limit="256.35" upper_limit="490.05"/>
                    <measurement group_id="O2" value="365.40" lower_limit="294.25" upper_limit="436.55"/>
                    <measurement group_id="O3" value="404.00" lower_limit="329.60" upper_limit="478.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Days to the Return of Baseline Platelet Function in All Treatment Arms (Adjusted for Level of Inhibition 24 Hours Post-LD) by LTA (5 and 20 μM ADP)</title>
        <description>Maximum platelet aggregation (MPA) to 5 and 20 μM ADP were assessed by LTA. This outcome measure was not analyzed due to limited sample size.</description>
        <time_frame>Up through 11 days</time_frame>
        <population>Since this outcome measure was not analyzed due to the limited sample size, zero participants were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Clopidogrel 600 mg</title>
            <description>Clopidogrel 600 mg taken orally, day one, single dose (Loading Dose [LD])</description>
          </group>
          <group group_id="O2">
            <title>Prasugrel 60 mg</title>
            <description>Prasugrel 60 mg taken orally, day one, single dose (Loading Dose [LD])</description>
          </group>
          <group group_id="O3">
            <title>Prasugrel 30 mg</title>
            <description>Prasugrel 30 mg taken orally, day one, single dose (Loading Dose [LD])</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Days to the Return of Baseline Platelet Function in All Treatment Arms (Adjusted for Level of Inhibition 24 Hours Post-LD) by LTA (5 and 20 μM ADP)</title>
          <description>Maximum platelet aggregation (MPA) to 5 and 20 μM ADP were assessed by LTA. This outcome measure was not analyzed due to limited sample size.</description>
          <population>Since this outcome measure was not analyzed due to the limited sample size, zero participants were included in the analysis.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Days to the Return of Baseline Platelet Function in All Treatment Arms (Adjusted for Level of Inhibition 24 Hrs Post-LD) by Multiplate® ADP Test and ADP Test High Sensitivity (HS)</title>
        <description>The Multiplate analyzer was used to assess platelet aggregation based on impedance aggregometry in whole blood. After adding 6.4 µM ADP (ADP test) or 6.4 µM ADP plus 9.4 nM Prostaglandin E1 (PGE1) (ADP test HS), area under the aggregation curve (AUC) was calculated. This outcome measure was not analyzed due to limited sample size.</description>
        <time_frame>Up through 11 days</time_frame>
        <population>Since this outcome measure was not analyzed due to the limited sample size, zero participants were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Clopidogrel 600 mg</title>
            <description>Clopidogrel 600 mg taken orally, day one, single dose (Loading Dose [LD])</description>
          </group>
          <group group_id="O2">
            <title>Prasugrel 60 mg</title>
            <description>Prasugrel 60 mg taken orally, day one, single dose (Loading Dose [LD])</description>
          </group>
          <group group_id="O3">
            <title>Prasugrel 30 mg</title>
            <description>Prasugrel 30 mg taken orally, day one, single dose (Loading Dose [LD])</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Days to the Return of Baseline Platelet Function in All Treatment Arms (Adjusted for Level of Inhibition 24 Hrs Post-LD) by Multiplate® ADP Test and ADP Test High Sensitivity (HS)</title>
          <description>The Multiplate analyzer was used to assess platelet aggregation based on impedance aggregometry in whole blood. After adding 6.4 µM ADP (ADP test) or 6.4 µM ADP plus 9.4 nM Prostaglandin E1 (PGE1) (ADP test HS), area under the aggregation curve (AUC) was calculated. This outcome measure was not analyzed due to limited sample size.</description>
          <population>Since this outcome measure was not analyzed due to the limited sample size, zero participants were included in the analysis.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Platelet Function by LTA at 5 and 20 μM ADP</title>
        <description>MPA to 5 and 20 μM ADP were assessed by LTA.</description>
        <time_frame>24 hours post-loading dose</time_frame>
        <population>LD ITT population: All randomized participants who received an LD with evaluable PD measurements 24 hours post-LD.</population>
        <group_list>
          <group group_id="O1">
            <title>Clopidogrel 600 mg</title>
            <description>Clopidogrel 600 mg taken orally, day one, single dose (Loading Dose [LD])</description>
          </group>
          <group group_id="O2">
            <title>Prasugrel 60 mg</title>
            <description>Prasugrel 60 mg taken orally, day one, single dose (Loading Dose [LD])</description>
          </group>
          <group group_id="O3">
            <title>Prasugrel 30 mg</title>
            <description>Prasugrel 30 mg taken orally, day one, single dose (Loading Dose [LD])</description>
          </group>
        </group_list>
        <measure>
          <title>Platelet Function by LTA at 5 and 20 μM ADP</title>
          <description>MPA to 5 and 20 μM ADP were assessed by LTA.</description>
          <population>LD ITT population: All randomized participants who received an LD with evaluable PD measurements 24 hours post-LD.</population>
          <units>percent aggregation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Maximum Aggregation (20 µM ADP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.60" spread="20.60"/>
                    <measurement group_id="O2" value="27.30" spread="10.86"/>
                    <measurement group_id="O3" value="31.67" spread="11.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maximum Aggregation (5 µM ADP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.40" spread="16.79"/>
                    <measurement group_id="O2" value="22.00" spread="11.44"/>
                    <measurement group_id="O3" value="25.50" spread="8.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Platelet Function by Multiplate® ADP Test and ADP Test HS</title>
        <description>The Multiplate analyzer was used to assess platelet aggregation based on impedance aggregometry in whole blood. After adding 6.4 µM ADP (ADP test) or 6.4 µM ADP plus 9.4 nM PGE1 (ADP test HS), area under the aggregation curve (AUC) were calculated.</description>
        <time_frame>24 hours post-loading dose</time_frame>
        <population>LD ITT Population: All randomized participants who received an LD with evaluable PD measurements 24 hours post-LD.</population>
        <group_list>
          <group group_id="O1">
            <title>Clopidogrel 600 mg</title>
            <description>Clopidogrel 600 mg taken orally, day one, single dose (Loading Dose [LD])</description>
          </group>
          <group group_id="O2">
            <title>Prasugrel 60 mg</title>
            <description>Prasugrel 60 mg taken orally, day one, single dose (Loading Dose [LD])</description>
          </group>
          <group group_id="O3">
            <title>Prasugrel 30 mg</title>
            <description>Prasugrel 30 mg taken orally, day one, single dose (Loading Dose [LD])</description>
          </group>
        </group_list>
        <measure>
          <title>Platelet Function by Multiplate® ADP Test and ADP Test HS</title>
          <description>The Multiplate analyzer was used to assess platelet aggregation based on impedance aggregometry in whole blood. After adding 6.4 µM ADP (ADP test) or 6.4 µM ADP plus 9.4 nM PGE1 (ADP test HS), area under the aggregation curve (AUC) were calculated.</description>
          <population>LD ITT Population: All randomized participants who received an LD with evaluable PD measurements 24 hours post-LD.</population>
          <units>aggregation units*minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ADP Test AUC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="248.80" spread="120.54"/>
                    <measurement group_id="O2" value="90.00" spread="27.46"/>
                    <measurement group_id="O3" value="118.17" spread="46.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADP Test HS AUC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166.80" spread="82.24"/>
                    <measurement group_id="O2" value="34.50" spread="28.33"/>
                    <measurement group_id="O3" value="70.17" spread="36.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Clopidogrel 600 mg</title>
          <description>Clopidogrel 600 mg taken orally, day one, single dose (Loading Dose [LD])</description>
        </group>
        <group group_id="E2">
          <title>Prasugrel 60 mg</title>
          <description>Prasugrel 60 mg taken orally, day one, single dose (Loading Dose [LD])</description>
        </group>
        <group group_id="E3">
          <title>Prasugrel 30 mg</title>
          <description>Prasugrel 30 mg taken orally, day one, single dose (Loading Dose [LD])</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Trial was terminated early due to enrollment futility which resulted in limited data and the inability to analyze some outcome measures.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

